Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17β-estradiol combined with sequential 5-20 mg dydrogesterone

References

• van de Weijer PHM, Barentsen R, Kenemans P. Women's expectations and acceptance of cyclic induced HRT bleeds. Maturitas 1998;30:257–63
   PubMed Web of Science ®Google Scholar
• The Writing Group for the PEP trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Post-menopausal Estrogen/Progestin Interventions trial. J Am Med Assoc 1996;275:370–5
   Google Scholar
• Woodruff JD, Pickar JH. Incidence of endo-metrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gyneco/ 1994;170: 1213–23
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continu-ous combined oestrogen—progestogen replace-ment therapy. Br J Obstet Gynaecol 2000;107: 1392–400
   Google Scholar
• Ferenczy A, Gelfand MM. Endometrial histology and bleeding patterns in postmenopausal women taking sequential, combined estradiol and dydro-gesterone. Maturitas 1997;26:219–26
   PubMed Web of Science ®Google Scholar
• Beresford SAA, Weis NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458–61
   PubMed Web of Science ®Google Scholar
• Lacey RW, Howson GL, Sampson GA. Safety of progestins: effects of dydrogesterone on blood lipids. Br J Gun Pract 1983;(Suppl 24):4–10
   Google Scholar
• Roux C, Kolta S, Chappard C, Morieux C, Dougados M, De Vernejoul MC. Bone effects of dydrogesterone in ovariectomised rats: a bio-logic, histomorphometric and densitometric study. Bone 1996;19:463–8
   Google Scholar
• van de Weijer PHM, Scholten P, van der Mooren MJ, Barentsen R, Kenemans P. Bleeding patterns and endometrial histology during administration of low dose estradiol sequentially combined with dydrogesterone. Climacteric 1999;2:1–9
   Google Scholar
• Stevenson JC, Teter P, Lees B. 17[3-0estradiol (1 mg/day) continously combined with dydro-gesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women. Maturitas 2001;38: 197–203
   Google Scholar
• Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage micronised 17[3-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479–88
   PubMed Web of Science ®Google Scholar
• Burch DJ, Spowart KJM, Jessinger DK, Randall S, Smith SK. A dose-ranging study of the use of cyclical dydrogesterone with continuous 17[3-oestradiol. Br J Obstet Gynaecol 1995;102: 243–8
   Google Scholar
• van de Weijer PHM, Mol M, Biesheuvel E. Vaginal bleeding patterns in sequential regimens of 2 mg oestradiol with dydrogesterone. Eur Menopause J 1995;4:9–16
   Google Scholar
• Boerrigter PJ, van de Weijer PHM. Hormone replacement therapy and endometrial monitor-ing. Eur Menopause J 1995;2:2
   Google Scholar
• Committee for Proprietary Medicinal Products. Points to consider on hormone replacement therapy. London: CPMP, 19 November 1997
   Google Scholar
• Legault C, Wasilauskas C. Local versus central readings of endometrial biopsies in a multicenter clinical trial. Control Clin Trials 1996;17:2S
   Google Scholar
• Betsey EM, Carlson N. The description of menstrual bleeding patterns: towards fewer measures. Stat Med 1991;10:267–84
   PubMed Web of Science ®Google Scholar
• van der Mooren MJ, Hanselaar AG, Born GF, Rolland R. Changes in the withdrawal bleeding pattern and endometrial histology during 1713-oestradiol—dydrogesterone therapy in postmeno-pausal women: a 2-year prospective study. Maturitas 1994;20:175–80
   PubMed Web of Science ®Google Scholar
• Bergeron C, Fox H. Low incidence of endo-metrial hyperplasia with acceptable bleeding patterns in women taking sequential hormone replacement therapy with dydrogesterone. Gynecol Endocrinol 2000;15:275–81
   Google Scholar
• Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Patlwl 2000;190: 462–9
   PubMed Web of Science ®Google Scholar
• Archer DF. Endometrial morphology in asymp-tomatic women. Am J Obstet Gynecol 1991;165: 317–22
   PubMed Web of Science ®Google Scholar
• Becker FF. Recent concepts of initiation and pro-motion in carcinogenesis. Am J Pathol 1981;105: 3–9
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Yaqub N, King ME. A compari-son of the Pipette device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipette device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol 1993;168:55–9
   Google Scholar
• Ferenczy A, Mutter G. Endometrial hyperplasia and neoplasia: definition, diagnosis and manage-ment principles. In Droegemuller W, Sciarra J, eds. Gynecology and Obstetrics. Philadelphia: Lippincott Williams & Wilkins, 2000;4
   Google Scholar
• Krampl E. How representative are Pipette endo-metrial biopsies? Gynaecol Endosc 1997;6: 277–81
   Google Scholar
• Goldchmit R, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial Pipette sampling with and without sonographic measurement of endometrial thickness. Obstet Gynecol 1993;82: 727–30
   Google Scholar
• Clisham PR, de Ziegler D, Lozano K, Judd HL. Comparison of continuous versus sequential estrogen and progestin therapy in postmeno-pausal women. Obstet Gynecol 1991;77:241–6
   PubMed Web of Science ®Google Scholar
• Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O'Dowd T. Amenorrhea and endo-metrial atrophy with continuous oral estrogens and progestogen in postmenopausal women. Obstet Gynecol 1985;65:496–9
   Google Scholar
• van de Weijer PHM, Barentsen R, De Vries M, Kenemans P. Relationship of estradiol levels to breakthrough bleeding during continuous com-bined hormone replacement therapy. Obstet Gynecol 1999;93:551–7
   PubMed Web of Science ®Google Scholar
• Burch D, Biesheuvel E, Smith S, Fox H. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy? Maturitas 2000;34: 155–60
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Barlow DH, Ulrich LG, et al. Is the timing of withdrawal bleeding a guide to endo-metrial safety during sequential oestrogen—progestagen replacement therapy? Lancet 1994; 344:979–82
   PubMed Web of Science ®Google Scholar
• Amy JJ. Femoston®: effects on bone and quality-of-life. Eur Menopause J 1995;2:16–22
   Google Scholar
• Foster RH, Balfour JA. Estradiol and dydro-gesterone. A review of their combined use as hormone replacement therapy in postmeno-pausal women. Drugs Aging 1997;11:309–32
   Google Scholar